<span item_type="fundamental" item_id="e6dca749a24400d491efb152d79c5f34" counter_id="ST/US/HRMY" env="prod"></span><span item_type="announcement" item_id="574690698639514241" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 239 M, beating the estimate of USD 220.04 M.</p><p></p><h3>Financial Metrics</h3><h4>Segment Revenue</h4><ul><li>WAKIX® (pitolisant) franchise delivered net revenue of approximately $239 million in Q3 2025, representing a 29% year-over-year revenue growth.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm"></span></li></ul><h4>Operational Metrics</h4><p>The reference does not provide specific operational metrics such as net income, gross margin, operating profit, operating margin, or operating costs for the third quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023x8k.htm"></span></p><h4>Cash Flow</h4><p>There is no information provided regarding operating cash flow or free cash flow in the reference text.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023x8k.htm"></span></p><h4>Unique Metrics</h4><p>No unique company-specific financial indicators are mentioned in the reference text.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023x8k.htm"></span></p><h3>Outlook / Guidance</h3><ul><li>Harmony Biosciences has increased its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm"></span></li><li>The company anticipates continued growth and market opportunity for WAKIX, positioning it towards potential blockbuster status in narcolepsy treatment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm"></span></li><li>Full Q3 2025 earnings will be reported on November 4th, 2025, with a conference call scheduled to discuss the results.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm"></span></li></ul>

Harmony Biosciences | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 239 M